Related Experiment Videos
Retinoic acid syndrome: a case report
1Department of Internal Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Zhonghua Yi Xue Za Zhi = Chinese Medical Journal; Free China Ed
|March 24, 1998
Summary
All-trans-retinoic acid (ATRA) effectively treats acute promyelocytic leukemia (APL). However, some patients develop a dangerous complication known as ATRA syndrome, which requires careful monitoring and management.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- All-trans-retinoic acid (ATRA) is a key differentiation therapy for acute promyelocytic leukemia (APL).
- ATRA induces complete remission in most APL patients.
- A significant subset of patients (approximately 25%) treated with ATRA experience potentially fatal complications.
Observation:
- The study reports a case of an APL patient with leukocytosis and subacute disseminated intravascular coagulopathy.
- This patient developed the retinoic acid syndrome (RA syndrome) during ATRA treatment.
Findings:
- The case highlights the occurrence of RA syndrome in an APL patient presenting with specific clinical features.
- RA syndrome encompasses severe complications like respiratory distress, fever, effusions, renal failure, and hypotension.
Implications:
- This case underscores the importance of recognizing and managing RA syndrome in APL patients undergoing ATRA therapy.
- Early identification and intervention are crucial for mitigating the life-threatening risks associated with RA syndrome.
- Further research may focus on predictive markers and preventative strategies for RA syndrome.